Bergen, Norway,7 January 2022 -BerGenBioASA (OSE: BGBIO) (the “Company”), has been notified that Martin Olin, CEO and primary insider of BerGenBio ASA, has bought 10,000 shares in BerGenBio ASA at an average price of NOK 20.43 per share. After the transaction Mr. Olin holds 28,000 shares in BerGenBio ASA. Please see the attached document for further … Read more
Bergen, Norway,7 January 2022 -BerGenBioASA (OSE: BGBIO) (the “Company”), has been notified that Martin Olin, CEO and primary insider of BerGenBio ASA, has bought 10,000 shares in BerGenBio ASA at an average price of NOK 20.03 per share. After the transaction Mr. Olin holds 18,000 shares in BerGenBio ASA. Please see the attached document for further details … Read more
Bergen, Norway, 6 January 2022- BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, announces today the appointment of Anders Tullgren to succeed Sveinung Hole as Chairman of the Board of Directors, effective today. Sveinung Hole has been Chairman of the Board since March 2019 and … Read more
Bergen, Norway, 6 January 2022 – BerGenBio ASA (OSE:BGBIO) announces that an extraordinary general meeting in the Company was held on 6 January 2022. All proposals were resolved as presented in the notice convening the extraordinary general meeting distributed on 16 December 2022, as further set out in the minutes from the extraordinary general meeting … Read more
Bergen, Norway,6 January 2022 -BerGenBioASA (OSE: BGBIO) (the “Company”), has been notified that Martin Olin, CEO and primary insider of BerGenBio ASA, has bought 8,000 shares in BerGenBio ASA at an average price of NOK 19.87 per share. After the transaction Mr. Olin holds 8,000 shares in BerGenBio ASA. Please see the attached document for further … Read more
Bergen, Norway, 16 December 2021 – Notice is hereby given that an Extraordinary General Meeting in BerGenBio ASA (OSE:BGBIO) will be held on 6 January 2022 at 10:00 hours (CET). The notice, registration form and power of attorney are attached to this release. The notice will be sent to all registered shareholders and is available at … Read more
In-Licensing further strengthens intellectual property estate for the treatment of Non-Small Cell Cancer (NSCLC) patients with STK11 mutations Bergen, Norway, 16 December 2021- BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL inhibitors for severe unmet medical needs, announced today the licensing of certain intellectual property from the UT Southwestern Medical Center. The … Read more
Bergen, Norway, 14 December 2021- BerGenBio ASA (OSE:BGBIO), BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, is pleased to announce that it will be presenting at the 12th DNB Nordic Healthcare Conference on 16th December 2021. The presentation will take place from 11:35 CET … Read more
Bergen, Norway, 13 December 2021- BerGenBio ASA (OSE:BGBIO), BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, is pleased to announce that it is presenting updated data from the Company’s Phase II study of bemcentinib (BCBC003) in a poster presentation today at the 63rd Annual … Read more
Bergen, Norway, 17 November 2021 – Reference is made to the stock exchange notice published by BerGenBio ASA (the “Company”) (OSE: BGBIO) on 9 November 2021 where the Company announced that the board of directors of the Company had resolved to increase the Company’s share capital in connection with the exercise of options pursuant to … Read more
soug@oncoinvent.com
Oystein Soug has over 15 years of experience in biotechnology, holding several management positions. Most recently, Mr. Soug was CEO of Arxx Therapeutics, where he led the company to initiate the clinical programme and was responsible for the merger with Dutch pharma company Oxitope Pharma to create Calluna Pharma. Prior to Arxx, he served as CFO and then CEO of Targovax, an Oslo listed biotechnology company, which went public during Mr. Soug’s tenure. Mr. Soug started his career in biotech as CFO of Oslo-listed radiopharmaceutical company Algeta. During this period, the company conducted a successful phase 3 trial, launched its radium-223 based prostate cancer drug Xofigo® and out-licensed the drug. Mr. Soug co-led the sale of the company to Bayer in 2014.
Mr. Soug holds an MSc in Economics and
Financial Markets from Universität St. Gallen in Switzerland in 1997
mansson@oncoinvent.com
Anders Månsson is a business executive with over 25 years of experience from management roles in the pharmaceutical industry, focusing on commercialisation and M&A + licensing. Mr. Månsson has held leading roles in the industry both in his native Sweden and in other European countries, and he has worked extensively with the USA and Asia as focus markets in global roles.
Mr. Månsson holds a B.Sc. degree in Business & Economics from Lund’s University in Sweden as well as an MBA from Business School Lausanne in Switzerland. He has a broad-based industrial experience, featuring both large multinational companies such as Meda, Ferring & LEO Pharma, and including leading roles in start-ups and smaller biotech companies. On top of his executive role in Oncoinvent, Mr. Månsson holds two non-executive director positions serving on the board of EQL Pharma AB as well Immetric AB, the latter being an investment company focusing on life science.